Hepatitis B Hope vs Trust
A potential cure sparks optimism — but pharma distrust could slow adoption
How hopeful does bepirovirsen's 20% cure rate make you feel about future treatments?
On this page
Share It On
Executive summary
A potential breakthrough in hepatitis B treatment is generating rare public optimism — and revealing deep structural fault lines in how Americans trust the institutions delivering it. When 237 Americans were told that bepirovirsen, an experimental drug, achieved a functional cure in roughly one in five patients during Phase 3 trials, 86% said they felt hopeful about the future of medicine. That number deserves context: current standard-of-care therapy cures fewer than 1% of patients per year, making this a roughly 20-fold improvement.
But beneath the headline optimism, the survey surfaces three forces that could slow real-world adoption. Safety anxiety and doubts about data adequacy dominated open-ended responses. Pharmaceutical trust is structurally low — only 16% of Americans trust drugmakers to prioritize patients over profits. And the populations who need this drug most, in sub-Saharan Africa and the Western Pacific, face affordability barriers that no FDA approval will automatically remove.
With the FDA's Breakthrough Therapy Designation secured and a decision deadline of October 26, 2026, the clinical case for bepirovirsen is nearly made. The public health case is still being built.
Context
Hepatitis B is one of the most consequential infectious diseases on earth — and one of the most neglected in Western public discourse. The WHO estimates 254 million people live with chronic infection globally, with 1.1 million deaths annually from cirrhosis and liver cancer. The burden falls disproportionately on the Western Pacific region (97 million cases) and sub-Saharan Africa (65 million), regions where treatment access, not clinical efficacy, has historically been the binding constraint.
For decades, the standard of care has been nucleoside analogues — oral antivirals that suppress the virus but rarely eliminate it. Patients take them indefinitely, and the functional cure rate (defined as sustained loss of hepatitis B surface antigen, or HBsAg) runs below 1% per year. The virus is managed, not beaten.
Bepirovirsen, developed by GSK, is an antisense oligonucleotide that works differently: it targets the viral RNA directly, aiming to deplete HBsAg and break the cycle that allows the virus to persist. In the Phase 3 B-Well 1 and B-Well 2 trials — together enrolling 1,838 patients — a functional cure was achieved in approximately 20% of bepirovirsen patients versus 0% of placebo patients at week 72. The results were published in the New England Journal of Medicine. The FDA granted Breakthrough Therapy Designation on April 28, 2026, and set a PDUFA review deadline of October 26, 2026.
This survey, conducted with 237 U.S. adults, was designed to read the public's reaction to that clinical milestone — measuring optimism, safety concerns, trust in the pharmaceutical system, and the practical priorities patients bring to decisions about chronic disease management. The findings land at a critical inflection point: a drug that could reshape hepatitis B treatment is weeks away from a regulatory verdict, and the public's readiness to embrace it is far from guaranteed.
Findings
Public optimism runs high — and it's grounded in clinical math
Eighty-six percent of respondents said they felt either "somewhat hopeful" (45.6%) or "very hopeful" (40.1%) about the future of medical treatments after learning about bepirovirsen's Phase 3 results. Only 7.2% said they were not very hopeful. That breadth of positive sentiment is notable on its own — but it becomes striking when you understand the benchmark it's reacting to.
Current nucleoside analogue therapy achieves a functional cure in fewer than 1 in 100 patients per year. Bepirovirsen hit 1 in 5 — roughly a 20-fold improvement — with the placebo arm achieving zero cures at the same timepoint. For 254 million people globally living with a disease that requires lifelong medication management and still kills more than a million people annually, the emotional resonance of that number is straightforward. This isn't incremental progress. It's a category shift.
The FDA's response underscores the magnitude: Breakthrough Therapy Designation, granted April 28, 2026, is reserved for drugs showing "substantial improvement over available therapies." The regulatory clock is now running toward an October 26, 2026 decision date.
Takeaway: What would matter most with a chronic condition requiring daily medication?
Takeaway: What would matter most with a chronic condition requiring daily medication?
Data Adequacy
A group of respondents highlight a lack of data as a key issue, while others are comfortable with the existing evidence, representing opposite positions on evidence sufficiency.
Hover over dots to see real answers.
Respondents split sharply on whether existing evidence is enough — some see no worries at all, while others cite insufficient testing as their central concern.
Highlighted answers
- Data are insufficient, raising worries
“My biggest concern with new experimental drugs is safety. I would want to know what the long-term effects could be, how many people have actually been tested, and whether the benefits truly outweigh the risks. I also worry about side effects that may not show up right away, especially if the drug”
This respondent articulates the full spectrum of data-adequacy worries — trial size, long-term evidence, and risk-benefit balance — that could slow real-world adoption.
- Data are insufficient, raising worries
“NOT enough data”
A blunt, unambiguous declaration that the evidence base is inadequate, representing the low-pole position in its simplest form.
- Data are insufficient, raising worries
“no long term studies”
Flags the absence of longitudinal data — a legitimate gap even in Phase 3 trials — as the core evidence concern.
- Data are insufficient, raising worries
“They are not tested enough to ensure they don't cause harm”
Directly equates insufficient testing with potential harm, capturing the causal logic driving data-adequacy skepticism.
- Data are sufficient, no data‑related worries
“I have zero concern.”
Represents the opposite pole — complete comfort with the existing evidence — highlighting the sharp polarization the survey uncovered.
Conclusion
The FDA's October 2026 decision on bepirovirsen will be a clinical verdict. What this survey makes clear is that the public health verdict will take longer — and will be decided on different terms.
The optimism is real and grounded: 86% of Americans who heard about a 20-fold improvement in hepatitis B cure rates responded with hope. But that hope sits on top of a low-trust foundation that could delay uptake, fuel hesitancy, and — in the worst case — hand critics an opening to cast doubt on an approval that the clinical evidence strongly supports.
Three things will shape what comes next. First, how GSK and regulators communicate the safety profile: the 16% rate of grade 3+ adverse events is a real number, and patients who encounter it without context will be alarmed. Proactive, transparent messaging beats reactive damage control. Second, whether pricing decisions reflect the populations most burdened by hepatitis B, not just the markets most profitable to serve. And third, whether the patient community — already the most concerned demographic in this survey — becomes an advocate or a skeptic. That group will be reached through peer voices and lived experience, not institutional claims.
Watch the PDUFA date. But more importantly, watch what happens the day after approval.
See echo in five minutes.
Bring a question. Get a real answer from real people, on the AI they already use.